Protagenic Therapeutics, Inc.new Reports Material Event

Q: What did PTIX disclose in this 8-K?

PTIX reported that director Jennifer Chao resigned from the Board of Directors, effective November 3, 2025.

Q: When was the resignation of Jennifer Chao effective at PTIX?

The resignation was effective on November 3, 2025.

Q: Did PTIX report any disagreements related to the resignation?

The company stated there were no disagreements between Ms. Chao and the company.

Q: What section of the report covers this change at PTIX?

The disclosure appears under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements).

Q: Which exchange lists PTIX securities?

PTIX common stock and warrants are listed on Nasdaq.

Protagenic Therapeutics (PTIX) reported a board change: director Jennifer Chao resigned, effective November 3, 2025.

Accepted by SEC EDGAR 11/05/2025 - 04:21 PM EST

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Protagenic Therapeutics (PTIX) reported a board change: director Jennifer Chao resigned, effective November 3, 2025. The company stated there were no disagreements between Ms. Chao and the company. This is a routine governance update disclosed under a change in directors or certain officers.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PTIX disclose in this 8-K?

PTIX reported that director Jennifer Chao resigned from the Board of Directors, effective November 3, 2025.

When was the resignation of Jennifer Chao effective at PTIX?

The resignation was effective on November 3, 2025.

What section of the report covers this change at PTIX?

The disclosure appears under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements).

Which exchange lists PTIX securities?

PTIX common stock and warrants are listed on Nasdaq.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): November 3, 2025

PROTAGENIC THERAPEUTICS, INC.

Protagenic Therapeutics, Inc.\new

(Exact name of Company as specified in its charter)

Delaware

001-12555

06-1390025

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

149 Fifth Avenue, Suite 500, New York, NY		10010
(Address of principal executive offices)		(Zip Code)

212-994-8200

(Company’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Protagenic Therapeutics, Inc. Common Stock	PTIX	Nasdaq
Protagenic Therapeutics, Inc. Common Stock Warrants	PTIXW	Nasdaq

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 3, 2025, Jennifer Chao resigned from the Board of Directors of Protagenic Therapeutics, Inc. (the “Company”), effective immediately. There were no disagreements between Ms. Chao and the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROTAGENIC THERAPEUTICS, INC.

Date: November 5, 2025	By:	/s/ Alexander K. Arrow
	Name:	Alexander K. Arrow
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR